Characterization of a pneumococcal meningitis mouse model by Mook-Kanamori, Barry et al.
RESEARCH ARTICLE Open Access
Characterization of a pneumococcal meningitis
mouse model
Barry Mook-Kanamori
1†, Madelijn Geldhoff
1†, Dirk Troost
2, Tom van der Poll
3 and Diederik van de Beek
1,4*
Abstract
Background: S. pneumoniae is the most common causative agent of meningitis, and is associated with high
morbidity and mortality. We aimed to develop an integrated and representative pneumococcal meningitis mouse
model resembling the human situation.
Methods: Adult mice (C57BL/6) were inoculated in the cisterna magna with increasing doses of S. pneumoniae
serotype 3 colony forming units (CFU; n = 24, 10
4,1 0
5,1 0
6 and 10
7 CFU) and survival studies were performed.
Cerebrospinal fluid (CSF), brain, blood, spleen, and lungs were collected. Subsequently, mice were inoculated with
10
4 CFU S. pneumoniae serotype 3 and sacrificed at 6 (n = 6) and 30 hours (n = 6). Outcome parameters were
bacterial outgrowth, clinical score, and cytokine and chemokine levels (using Luminex
®) in CSF, blood and brain.
Meningeal inflammation, neutrophil infiltration, parenchymal and subarachnoidal hemorrhages, microglial activation
and hippocampal apoptosis were assessed in histopathological studies.
Results: Lower doses of bacteria delayed onset of illness and time of death (median survival CFU 10
4, 56 hrs; 10
5,
38 hrs, 10
6, 28 hrs. 10
7, 24 hrs). Bacterial titers in brain and CSF were similar in all mice at the end-stage of disease
independent of inoculation dose, though bacterial outgrowth in the systemic compartment was less at lower
inoculation doses. At 30 hours after inoculation with 10
4 CFU of S. pneumoniae, blood levels of KC, IL6, MIP-2 and
IFN- g were elevated, as were brain homogenate levels of KC, MIP-2, IL-6, IL-1b and RANTES. Brain histology
uniformly showed meningeal inflammation at 6 hours, and, neutrophil infiltration, microglial activation, and
hippocampal apoptosis at 30 hours. Parenchymal and subarachnoidal and cortical hemorrhages were seen in 5 of
6 and 3 of 6 mice at 6 and 30 hours, respectively.
Conclusion: We have developed and validated a murine model of pneumococcal meningitis.
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Background
Bacterial meningitis is a life threatening infectious disease
of the central nervous system (CNS). The annual inci-
dence is estimated to be up to 2.6 to 6.0 cases per 100 000
in Europe and may be up to ten times higher in develop-
ing countries [1,2]. The most common pathogen beyond
the neonatal period is Streptococcus pneumoniae [1,3],
causing 70% of cases. Despite advances in medical care,
mortality from pneumococcal meningitis remains between
16% and 37% and neurological sequelae affect 30-52% of
survivors [4-6]. There is a continuing need for the devel-
opment of new treatment strategies.
Complications associated with pneumococcal meningitis
include cerebral infarction, hemorrhages, motor and sen-
sory deficit, seizures, memory and learning impairments,
and hearing loss [2,7,8]. Autopsy studies of patients who
died following pneumococcal meningitis revealed cerebral
edema, cerebral infarctions and hemorrhages, apoptosis
and necrosis of the hippocampal dentate gyrus [9-11].
Many of these pathological features have been reproduced
in animal models, which provide the setting for novel drug
development and pathophysiological studies [12,13].
Several murine models have been developed, using
intracerebral [14,15], intraperitoneal [16], intravenous
[16], intranasal [17] or intracisternal inoculation methods
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with reproducibility, limited disease progression or iatro-
genic structural damage, combined with a need for a sin-
gle model in which most pathological features seen in
human pneumococcal meningitis can be measured, has
fueled the development of new animal models. Here we
describe the development of an adult mouse model of
pneumococcal meningitis in which many of the human
pathological features are demonstrated.
Methods
A clinical isolate of S. pneumoniae serotype 3 was
obtained from ATCC (catalog number 6303), and was
grown to mid log phase in 4 hours at 37°C in Todd-
Hewitt broth supplemented with 0.5% yeast extract. At
an OD620 of 0.8 to 1.0 the S. pneumoniae were centri-
fuged and washed twice by resuspension in sterile 0.9%
NaCl and recentrifugation. Finally, the bacteria were
resuspended in sterile NaCl 0.9% to yield an approximate
concentration of 1 × 10
9 colony forming units (CFU)/ml.
The exact number of CFUs was subsequently determined
for inoculates by serial dilution method and on blood
agar plates (overnight at 37°C).
Animal experiments were approved by the Institutional
Animal Care and Use Committee of the Academic Medi-
cal Center, Amsterdam. To determine the inoculation
dose and optimal time points of sacrifice, 24 8-10 week
old male C57BL/6 mice (Charles River Laboratories,
Germany) received 0.1 mg/kg s.c. buprenorphine and
short-term anesthesia using 1.5-2.0% isoflurane during
inoculation. The mice were divided into 4 groups, each
receiving a different concentration of bacterial inoculum
(10
4,1 0
5,1 0
6 and 10
7 CFU S. pneumoniae per mouse; n =
6 per dose). Inoculation was conducted by injecting 10 μL
of bacterial suspension into the cisterna magna using a 32-
gauge needle. All animals were evaluated directly following
inoculation and subsequently at 4-hour intervals. The fol-
lowing scoring was used (Table 1): range: 0-41 pts; each
scoring parameter ranging from 0, corresponding to no
deficit, to a variable maximum score. The maximum score
was determined by the estimated contribution of the vari-
able to overall health of the mouse): weight loss (0-4 pts),
activity (0-4 pts), time to return to upright position (0-6
pts), state of skin/fur (0-3 pts), posture (0-2 pts), eye dis-
charge or protrusion (0-4 pts), respiration rate (0-4 pts),
irregular/labored breathing (0-4 pts), epilepsy, limb paresis
or ataxia (0-10pts). The clinical course was divided into a
pre-symptomatic period (from time of inoculation until
clinical score ≤ 10) and symptomatic period (clinical score
> 10 until death/sacrifice). Survival studies were performed
and cerebrospinal fluid (CSF), brain, blood, spleen, and
lungs were collected post mortem. After determin-
ing inoculation dose and time-points of sacrifice, the
model was further characterized using 12 additional mice
inoculated with 10
4 CFU S. pneumoniae serotype 3 and
sacrificed at 6 (n = 6) and 30 hours (n = 6).
Bacterial titers were determined in samples of lung,
brain, and spleen (diluted 1:4 in sterile NaCl 0.9% and
homogenized). Blood was heparinized in a 1:4 dilution
and CSF was diluted 1:100 in sterile NaCl 0.9%. All bac-
terial titers were determined by plating serial dilutions
on blood agar plates and incubating overnight at 37 C.
Cytokine and chemokine measurement were performed
on the left cerebral hemisphere diluted 1:4 in sterile NaCl
0.9%, homogenized and lysed in lysis buffer (150 mM
N a C l ,1 5m MT r i s ,1m MM g C l ( H 2O)6,1m MC a C l 2
(H2O)2, 1% Triton, AEBSF 4 μg/ml, EDTA-NA2 50 μg/ml,
pepstatin 10 ng/ml, leupeptin 10 ng/ml, pH 7.4). Samples
of brain homogenate, serum and CSF were then centri-
fuged and supernatant stored at -80 C. Cytokine concen-
trations were determined with luminex
® technology using
a mouse cytokine and chemokine Bioplex kit (Bio-Rad
Laboratories, Veenendaal, The Netherlands).
All mice were perfused by cardiac puncture with PBS
prior to harvesting tissue. Histopathology was performed
on the right cerebral hemisphere fixed in 4% paraformalde-
hyde and paraffin embedded. Coronal 10 μm sections of
t h ee n t i r eh e m i s p h e r ew e r ec u tf o rs u b s e q u e n ts t a i n i n g .
Hematoxylin and eosin (HE) and Nissl staining were
performed to visualize hemorrhages, cortical necrosis, vas-
culitis and abscess formation. To determine neuronal
apoptosis in the dentate gyrus of the hippocampus, four
10 μm sections of the anterior, middle and posterior por-
tion of the hippocampus were stained with Caspase-3 anti-
bodies (polyclonal rabbit-anti-mouse, 1:100; Cell Signalling,
Danvers, MA). In each section, the total number of cas-
pase-3 positive cells was counted in both the dentate gyrus
(DG) and cornu ammonis (CA) regions. Scoring was inde-
pendently conducted by two investigators. Microglial acti-
vation was evaluated by immunohistochemistry using Iba-1
antibody (polyclonal rabbit-a n t i - m o u s e ,1 : 2 0 0 0 ;A B c a m ,
Cambridge, UK) staining of frontal lobe 10 μm sections.
No quantitative analysis was performed.
Comparisons of cytokine levels between groups were
calculated using the Mann-Whitney U test. A Kruskal-
Wallis one-way ANOVA was used to compare clinical
scores of pre-symptomatic and symptomatic periods.
Histopathological scores of neuronal apoptosis were com-
pared using Student’s t-test. For all analyses a p-value <
0.05 was considered significant.
Results
Mortality occurred in nearly all inoculated mice (Figure 1);
one mouse inoculated with 10
4 CFU survived beyond the
study window of 216 hours after inoculation and was
sacrificed. The median survival time was dose dependent
(10
4 CFU, 56 hrs; 10
5, 38 hrs, 10
6:, 28 hrs; 10
7, 24 hrs). To
approximate a physiological setting, we selected 10
4 CFU
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most animals would die if left untreated. Furthermore, for
future experimentation we chose 30 hours post inocula-
tion as the latest time point for sacrifice, at which all ani-
mals were still alive and the natural course of the infection
could be followed as long as possible.
Clinical scoring was performed on all mice in the survi-
val study. The average duration of the pre-symptomatic
period (clinical score ≤ 10) was dose dependent, and
increased approximately 1.5-fold with each successive
10-fold increase of bacterial inoculum concentration.
The duration of the symptomatic period did not differ
significantly between inoculation doses (mean, 11.7 hrs,
SD 4.8; Table 2).
Bacterial meningitis was confirmed in all 23 mice in the
survival study by way of culture of CSF and brain homo-
genate following death or sacrifice. The average pneumo-
coccal concentration in the CSF and brain homogenates
Table 1 Clinical score parameters, assessed values and weighted scores
Parameter Value Weighted score Maximum score
Weight loss from baseline 5% 0
10% 1
15% 2
20% 3
25% 4 4
Activity normal 0
increased/decreased 1
mildely deminished 1
deminished 2
severely deminished 3
coma 4 4
Time to return to upright normal 0
position upright < 5 sec 2
upright < 30 sec 4
no turn upright 6 6
Coat normal 0
deminished grooming 1
soiled 1
piloerection 1 3
Posture normal 0
sligh hunched back 1
sev hunched back 2 2
Eyes normal 0
protruding 1
sunken eyes 1
closed eyelids 1
discharge 1 4
Respiration rate (per min) > 150 0
< 150 1
< 100 2
<7 5 3
<5 0 4 4
Breathing irregular 2
laboured 2 4
Neurologic exam normal 0
ataxia 2
limb paresis/paralysis 2
epileptic seizure 2
status epilepticus 6 10
Total 41
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9 CFU/ml and 7.9 × 10
8 CFU/ml respectively.
Bacterial titers in de CNS compartment (CSF and brain)
did not increase with higher inoculation doses (Figure 2).
In comparison with the CNS compartment, in the sys-
temic compartment (blood, spleen, lung) bacterial con-
centrations were much lower (means 1.0 × 10
6,4 . 0×1 0
5
and 2.0 × 10
5 CFU/ml, respectively), and an increasing
bacterial titer was observed with each successive 10-fold
increase of bacterial inoculum concentration.
Mice with pneumococcal meningitis showed increased
plasma levels of KC at 6 hours (Figure 3; median 62 versus
213 pg/ml, P = 0.004) and 30 hours (median 62 versus
2031 pg/ml, P < 0.0001) compared to saline inoculated
mice. Furthermore, at 30 hours IL-6 (median 2 versus 202
pg/ml, P < 0.001), MIP-2 (median 5 versus 63 pg/ml, P =
0.002) and IFN-g (median 3 versus 16 pg/ml, P = 0.002)
were elevated in plasma of S. pneumoniae compared to
sham inoculated mice. IL-1b, IL-2, IL-4, IL-10, IL-12p70,
IL-17, RANTES, TNF-a, IL-18 and IL-33 were not signifi-
cantly altered in the plasmao fm i c ew i t hp n e u m o c o c c a l
meningitis compared to sham controls.
In brain homogenates, mice with pneumococcal menin-
gitis compared to saline inoculated mice showed elevated
levels of KC and MIP-2 at both 6 hours (Figure 3; KC
median 60 versus 393 pg/ml, P < 0.0001; MIP-2 median
45 versus 159 pg/ml, P = 0.003) and 30 hours (KC median
60 versus 18116 pg/ml, P < 0.0001; MIP-2 median 45 ver-
sus 10637 pg/ml, P < 0.0001) time points. IL-6 (median
20 versus 795 pg/ml, P < 0.0001), IL-1b (median 165 ver-
sus 939 pg/ml, P = 0.014), and RANTES (median 15
versus 1823 pg/ml, P < 0.0001) were increased at 30 hours
post infection in mice inoculated with pneumococcal
meningitis as compared to saline inoculated mice. IL-2,
IL-4, IL-10, IL-12p70, IL-17, IFN-g, TNF-a, IL-18 and IL-
33 were not altered in brain homogenates of mice with
pneumococcal meningitis compared to sham controls. In
CSF of mice with pneumococcal meningitis compared to
saline inoculated mice, IL-6 (median 26 versus 2772 pg/
ml, P = < 0.001), KC (median 84 versus 8369 pg/ml, P =
0.002), MIP-2 (median 63 versus 5542 pg/ml, P = 0.002)
and RANTES (median 21 versus 309 pg/ml, P = 0.005) are
elevated 30 hours post infection.
Histopathology at 6 hours after infection showed high
levels of meningeal inflammation in both peripheral and
ventricular CSF compartments, but none of the mice had
parenchymal lymphocytic infiltration, hemorrhages, micro-
glial activation, or hippocampal apoptosis (Figure 4A).
However, 30 hours after inoculation 3 of the 6 mice showed
parenchymal lymphocytic infiltration and pockets of bac-
teria were seen in 2 of 6 mice, located in the perivascular
spaces of the penetrating vasculature (Figure 4b). At
30 hours, 5 of 6 mice had one or more parenchymal, mainly
cortical, hemorrhages. Three mice demonstrated subarach-
noidal hemorrhages. Extensive diffuse microglial activation
was observed mice 30 hours after infection and at end
stage-stage of disease at all inoculation doses (Figure 4C),
although no quantitative analyses were performed. Neuro-
nal apoptosis in the dentate gyrus of the hippocampus was
Figure 1 Kaplan-Meier survival curve.F o u rg r o u p so f6m i c e
inoculated via direct intracisternal injection with 10
4,1 0
5,1 0
6 and
10
7 CFU of S. pneumoniae/mouse respectively.
Table 2 Duration of pre-symptomatic (time from inoculation to clinical score ≤ 10) and symptomatic (time from
clinical score > 10 to death/sacrifice) periods
Inoculation dose (CFU/mouse) 10e4 10e5 10e6 10e7 p-value
Pre-symptomatic period (hrs/st.dev) 40.7 (14.9) 26.1 (6.1) 18.7 (3.9) 12.0 (2.1) 0.001
Symptomatic period (hrs/st.dev) 9.1 (3.2) 13.0 (6.3) 10.8 (3.6) 13.6 (5.3) 0.557
Mean durations of the pre-symptomatic and symptomatic periods (expressed in hours) of the mice of the survival study. Mice were divided into 4 groups and
inoculated with 104 (5 mice, 1 mouse was excluded from analysis due to lack of any symptoms due to failed inoculation), 105 (6 mice), 106 (6 mice) and 107
CFU (6 mice) S. pneumoniae per mouse. Comparison of the clinical scores of pre-symptomatic and symptomatic periods was made using a Kruskal- Wallis one-
way ANOVA
Figure 2 Bacterial outgrowth. Bacterial titers in CSF, brain (central
nervous system compartment), and blood, spleen, and lung
(systemic compartment) at the end-stage of disease after
inoculation with 10
4,1 0
5,1 0
6 and 10
7 CFU S. pneumoniae per
mouse. Titers are expressed mean CFU/ml +/- S.E.M.
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Lower   Limit   of   Detection   (Brain/CSF/Plasma):   IL-1β   165/105/17;   IL-6   20/26/2;   IL-17   40/53/4;   IFN-γ   25/105/3;    KC   60/84/6;
RANTES   15/21/2;   TNF-α   60/420/8;   IL-18   135/210/14;   MIP-2   45/63/5;   VEGF   175/53/18;   IL-2   80/210/8;   IL-4   60/158/6;   IL-10
80/210/8;   IL-12p70   400/1050/40.
Figure 3 Cytokine levels in plasma, brain homogenates and CSF. Median concentrations (expressed in pg/ml) of cytokines in mice
inoculated with either NaCl or 10
4 CFU/mouse of S. pneumoniae and sacrificed after 30 hours, or 6 and 30 hours respectively. Comparisons of
cytokine levels between groups were calculated using the Mann-Whitney U test. (*P < 0.05; **P < 0.01).
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0.75. A significant increase in hippocampus neuronal apop-
tosis was observed at 30 hours post infection and was sig-
nificantly higher than saline infected mice (0.6 vs. 2.8 cells,
P < 0.001; Figure 5).
Discussion
We developed a murine model of pneumococcal menin-
gitis in which the histopathological and inflammatory
features as well as observed complications resemble
clinical and pathological findings in humans following
bacterial meningitis [1,20]. The most important features
of this model lie in the possibility of combining a rela-
tively low dose of inoculum and long period of disease
progression, allowing for a reproducible setting to exam-
ine clinical features as well as sufficient time to develop
the histopathological features seen in a human setting.
In previous murine models, pneumococcal meningitis
was established by either 1) direct bacterial inoculation
into the CNS, which generally very short survival times
A B
CD
E F
Figure 4 Brain pathology of mice with pneumococcal meningitis. Nissl staining of the cortex of mice infected with S. pneumoniae, showing
extensive leptomeningeal inflammatory infiltrate (A; 100× magnification), perivascular lymphocytic cuffing (B; 100× magnification), perivascular
lymphocytic infiltration combined with bacterial overgrowth (C; 200× magnification) and further bacterial overgrowth combined with
perivascular necrosis (D; 100× magnification). Iba-1 immunohistochemistry revealed microglial activation (E; 100× magnification). Hematoxylin
and eosin staining showed subarachnoidal and cortical hemorrhages (F; 100× magnification).
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cesses, or 2) intranasal or intraperitoneal inoculation
routes, which more closely models the longer physiolo-
gical inflammatory mechanisms [12]. Unfortunately,
mice inoculated via the intranasal or intraperitoneal
route often died as the result of sepsis or pneumonia,
and only 50% actually developed meningitis [17].
In this model the comparison of clinical score progres-
sion between mice with different inoculation doses lead to
the following conclusions: first, although the pre-sympto-
matic period was dose dependent (onset of symptoms
were later at lower doses of bacterial inoculation), the
duration of the symptomatic period was approximately
11.5 hours and similar between groups. This dose-depen-
dent delayed onset provides a model in which direct
inoculation in the CNS results in nearly 100% of mice
developing meningitis, combined with a prolonged pre-
symptomatic period in which various inflammatory
mechanisms may be studied. Second, the clinical features
contributing to deterioration were largely similar between
the 4 different inoculation groups. For example, at the
beginning of the symptomatic period (clinical score > 10)
the most important contributing factors of clinical dete-
rioration in all four inoculation groups were weight loss,
diminished activity and deficits during neurological exami-
nation. At the final clinical assessment during the survival
experiment, the most important additional factors of clini-
cal deterioration in all 4 groups were the time to turn to
upright position and increasing respiratory problems.
TNF-a,I L - 1a n dI L - 6a r ec o n s i d e r e dt ob et h ee a r l y
response proinflammatory cytokines that are upregulated
early in during pneumococcal meningitis [13]. Surpris-
ingly, TNF-a was not elevated at any time-point in our
model. Previous animal models demonstrated that TNF-
a was mainly increased during the first 6 to 24 hours of
the immune response [21,22]. However, human studies
show increased CSF levels of TNF-a but only early in the
course of the disease [23,24]. This discrepancy may be
explained by the lack of measurements that were per-
formed between 6 and 30 hours after infection. IL-1b,
which in humans is increased in the first 18 hours of
infection [25], was also markedly increased in brain
homogenates, but not in blood in our mice 30 hours
after infection. The IL-6 concentrations did significantly
increase CSF, brain homogenate and plasma 30 hours
after infection. This is consistent with other infection
models, in which IL-6, a cytokine displaying both pro-
and anti-inflammatory properties [26], has been shown
to be upregulated early during infection. In previous
pneumococcal meningitis models IL-6 was shown to be
involved in CSF leukocyte recruitment and possibly in
the regulation of blood brain barrier disruption [27]. The
anti-inflammatory cytokine IL-10, which has been shown
to downregulate TNF-a, IL-6 and KC was not measur-
ably increased at any time point [28].
Of the chemokines, the functional murine IL-8 homolo-
gue KC/CXCL1 and MIP-2/CXCL2 were both markedly
increased in CSF, brain homogenate and blood at 30
hours after infection. Furthermore, early upregulation of
KC and MIP-2 was also observed as early as 6 hours in
brain homogenate, but not in plasma, where only KC was
significantly increased. In humans, IL-8 has been shown to
AB
Figure 5 Neuronal apoptosis. Caspase-3 immunohistochemistry of 10 μm sections of the middle portion of the hippocampus of the right
cerebral hemisphere of mice inoculated with 10
4 CFU S. pneumoniae at 30 hrs post infection (panel A; 200× magnification). Mice inoculated
with S. pneumoniae showed significantly more hippocampal apoptosis at 30 hrs post infection than NaCl infected control mice (panel B,
expressed in mean number of Caspase-3 positive cells/section +/- S.E.M.; groups were compared using a Student’s t-test; *P < 0.001).
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yet in a rabbit meningitis model it was systemic IL-8 that
appeared to regulate CSF pleiocytosis [30]. MIP-2, which
is produced by astrocytes and microglial cells, but also by
monocytes and macrophages, has been shown in vitro to
be a chemoattractant for monocytes and neutrophils
recruitment [29].
B r a i nh i s t o p a t h o l o g yi no u rm o d e lr e s e m b l et h e
human situation in pneumococcal meningitis, We found
meningeal and parenchymal infiltration, (micro)hemor-
rhages, perivascular lymphocitic cuffing and perivascular
bacterial overgrowth, the beginning of abscess forma-
tion, microglial activation, and neuronal apoptosis in the
dentate hippocampal gyrus. Parenchymal (micro)hemor-
rhages were frequently observed (83%) and varied in
size and location. These results reflect findings in a
recent autopsy series in which microhemorrhages were
found in 10 of 16 (67%) patients who died of pneumo-
coccal meningitis [10]. In the clinical setting clinical set-
ting only 1-9% of all patients are documented to have
intracranial hemorrhagic complications [4], which is
likely to be an underestimation of the actual number of
hemorrhages as only radiological evidence was included.
In our model no cortical necrosis was observed at any
time point, including in mice that died in the survival
studies. Cerebral infarctions occur in approximately 30%
of patients with pneumococcal meningitis [5,20,31], and
cortical necrosis has been modeled successfully in sev-
eral rat and infant mouse meningitis models [18,22].
Possible reasons for the absence of necrosis may lie in
the duration from inoculation until sacrifice, the choice
of animal, age of the mice used, and antibiotic treat-
ments used in other models. The underlying mechan-
isms for both ischemic stroke and hemorrhages remain
unclear, though human CSF studies have suggested dys-
regulation of local coagulation cascade, complement
activation, and diffuse cerebral intravascular coagulopa-
thy [10,13,32].
The observations of microglial activation at 30 hours
after infection reflect in vitro findings in which microglial
cells are activated after exposure to S. pneumoniae [33].
Similarly, the delayed activation of microglial cells sup-
ports the results of a previous study in a rabbit model of
pneumococcal meningitis in which increased levels of the
microglial derived immunomodulatory protein activin A
was found at 12 hours after inoculation [34]. Microglia
represent a specific subset of cells related to monocytes
and dendritic cells and form the initial line of defense of
brain parenchyma against damage, injury and infection
and become activated in a toll-like receptor dependent
fashion upon pneumococcal exposure [35,36]. Upon acti-
vation, microglia produce large amounts of proinflamma-
tory cytokines, as well as reactive oxygen and nitrogen
intermediates, thereby possibly playing both neuroprotec-
tive and neurotoxic roles [13,37-39]. The role of micro-
glia during pneumococcal meningitis is largely unknown
at present, but interest has been fueled by the observation
that microglial activation in vitro is limited by corticos-
teroids treatment [40], which has become the standard
adjuvant therapy in the treatment of bacterial meningitis
in many countries [2,41].
Neuronal apoptosis was first observed in the human
autopsy studies of patients who died of bacterial meningi-
tis and was situated in the dentate gyrus of the hippocam-
pus [9]. Cognitive impairments and more specifically
learning difficulties have been attributed to hippocampal
apoptosis which has been modeled in mice, rats and rab-
bits [18,42,43]. Furthermore, the adjuvant treatment of
corticosteroids has been suggested as a possible factor
aggravating hippocampal apoptosis and reducing learning
capacity [42,44]. The process of apoptosis most likely
occurs in an early caspase independent and a late caspase
dependent mechanism [45]. In this model we were able to
detect the late stage caspase-3 dependent apoptosis at
30 hours post infection, providing an additional outcome
parameter for further pathophysiological and therapeutic
investigations.
Conclusions
The value of this mouse model is that it provides an
experimental setting of pneumococcal meningitis which is
highly reproducible, and provides several of the most valu-
able outcome parameters such as bacterial titers, menin-
geal and parenchymal infiltration, cytokine profiles,
microglial activation, neuronal apoptosis in the hippocam-
pus, perivascular infiltration and (micro) hemorrhages. We
feel that the integration of these pathological features,
which are characteristic of what is observed in human
autopsy studies into a single model, is a valuable tool in
the further investigation of both pathophysiological and
therapeutic intervention studies.
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